A Phase II, Randomized Study of the Safety and Efficacy of Hydroxyurea in Subjects on Potent Antiretroviral Therapy With Less Than 200 Copies/ml of HIV RNA in the Plasma

Inclusion Criteria You may be eligible for this study if you: * Are 13 years or older. * Have documented HIV-1 infection. * Are currently receiving combined IDV, ZDV(or D4T), and 3TC for at least 6 consecutive months, resulting in HIV RNA less than 200 copies/ml and CD4 cell count greater than 200 cells/mm3. * Had a CD4 count greater than 100 cells/mm3 before starting current anti-HIV therapy. * Are of childbearing age and agree to practice abstinence or use of combined barrier and hormonal methods of birth control during and for 3 months after the study. Exclusion Criteria You will not be eligible for this study if you: * Have taken various medications and have various laboratory results (see technical abstract). * Have cancer requiring chemotherapy. * Have an unexplained fever for 7 days or diarrhea for 15 days in the month before the start of the study. * Had prior peripheral neuropathy or hepatitis. * Recently underwent radiation, experimental, or infection therapy. * Are pregnant or breastfeeding.